Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian …
IB Vergote, F Joly, D Katsaros, C Coens, A Reinthaller… - 2012 - ascopubs.org
LBA5000 Background: The epidermal growth factor receptor (EGFR) has been found to be
overexpressed in 55-98% of advanced epithelial ovarian cancer. This trial evaluated the …
overexpressed in 55-98% of advanced epithelial ovarian cancer. This trial evaluated the …
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian …
IB Vergote, A Jimeno, F Joly, D Katsaros… - Journal of clinical …, 2014 - ascopubs.org
Purpose This trial evaluated the efficacy of maintenance erlotinib, an epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor, after first-line chemotherapy. Patients and …
factor receptor (EGFR) tyrosine kinase inhibitor, after first-line chemotherapy. Patients and …
A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND. 149)
H Hirte, A Oza, K Swenerton, SL Ellard, R Grimshaw… - Gynecologic …, 2010 - Elsevier
OBJECTIVES: Approximately 50% of ovarian cancers have elevated levels of epidermal
growth factor receptor (EGFR) which correlates with a poor prognosis. Preclinical evidence …
growth factor receptor (EGFR) which correlates with a poor prognosis. Preclinical evidence …
Report of first-stage accrual for NCI 5886, a phase II study of erlotinib, carboplatin and paclitaxel as first-line treatment of ovarian cancer
SV Blank, JP Curtin, NA Goldman… - Journal of Clinical …, 2006 - ascopubs.org
5076 Background: Abnormalities in the EGFR pathway are thought to play a major role in
the dysregulated growth of ovarian and related epithelial cancers. The purpose of this study …
the dysregulated growth of ovarian and related epithelial cancers. The purpose of this study …
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results …
AN Gordon, N Finkler, RP Edwards… - International Journal of …, 2005 - ijgc.bmj.com
The aim of this single-arm, phase II study was to estimate the tumor response rate and safety
profile of erlotinib HCl (erlotinib, Tarceva™, OSI-774) monotherapy in patients with …
profile of erlotinib HCl (erlotinib, Tarceva™, OSI-774) monotherapy in patients with …
A phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers
5017 Background: Epidermal growth factor receptor (HER1/EGFR) overexpression occurs in
over 50% of advanced epithelial ovarian carcinomas (EOC) and is associated with poor …
over 50% of advanced epithelial ovarian carcinomas (EOC) and is associated with poor …
Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma
HW Hirte - OncoTargets and therapy, 2013 - Taylor & Francis
The epidermal growth-factor receptor (EGFR) is overexpressed in the majority of epithelial
ovarian cancers and promotes cell proliferation, migration and invasion, and angiogenesis …
ovarian cancers and promotes cell proliferation, migration and invasion, and angiogenesis …
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment
SV Blank, P Christos, JP Curtin, N Goldman… - Gynecologic …, 2010 - Elsevier
BACKGROUND: The purpose of this study was to determine whether adding the anti-
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to …
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to …
Epidermal growth factor receptor (EGFR) pathway biomarkers in the randomized phase III trial of erlotinib versus observation in ovarian cancer patients with no …
E Despierre, I Vergote, R Anderson, C Coens… - Targeted …, 2015 - Springer
Background In this work, we aimed to identify molecular epidermal growth factor receptor
(EGFR) tissue biomarkers in patients with ovarian cancer who were treated within the phase …
(EGFR) tissue biomarkers in patients with ovarian cancer who were treated within the phase …
Preliminary results of a phase II study to evaluate gefitinib (ZD1839) combined with paclitaxel (P) and carboplatin (C) as second-line therapy in patients (pts) with …
P Pautier, F Joly, P Kerbrat, P Bougnoux… - Journal of Clinical …, 2004 - ascopubs.org
5015 Background: EGFR expression is increased in 35–70% of primary OC, and often
correlates with poor prognosis. Gefitinib (Iressa, ZD1839) is an orally active EGFR-TKI …
correlates with poor prognosis. Gefitinib (Iressa, ZD1839) is an orally active EGFR-TKI …